Kyodo Pharmaceutical: Announcement of Resolutions of the Thirteenth Meeting of the Third Board of Directors
Securities code: 300966 Securities abbreviation: Gongyong Pharmaceutical Announcement number: 2026-009 Convertible bond code: 123171 Convertible bond abbreviation: Gongyong convertible bonds
Hubei Tongyong Pharmaceutical Co., Ltd.
Announcement of Resolutions of the Thirteenth Meeting of the Third Board of Directors
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and that there are no false records, misleading statements or major omissions.
1. Convening of board of directors meetings
The 13th meeting of the third board of directors of Hubei Tongyong Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") was held on April 27, 2026 in the company's conference room by means of on-site combined with communication voting. Meeting notices and materials will be delivered by phone, WeChat and other communication methods on April 17, 2026. The meeting was chaired by the company’s chairman Xie Zubin. Nine directors were supposed to be present at the meeting, but 9 directors actually attended the meeting. Directors Zu Bin, Li Minglei, Qi Fei and He Deliang attended the meeting through communication voting. The company's senior managers attended the meeting.
The convening of this meeting complied with the provisions of the Company Law of the People's Republic of China (hereinafter referred to as the "Company Law"), the Articles of Association of Hubei Gongyong Pharmaceutical Co., Ltd. (hereinafter referred to as the "Articles of Association") and the "Rules of Procedure for the Board of Directors of Hubei Gongyong Pharmaceutical Co., Ltd.", and the resolutions of the meeting were legal and valid.
2. Review status of board of directors meeting
After careful deliberation and voting by all directors, the meeting considered the following proposals:
(1) Consideration and approval of the “Proposal on the Company’s 2025 Annual Report and its Summary”
After comprehensively reviewing the full text and summary of the company's 2025 annual report, the company's board of directors unanimously believes that: the company's 2025 annual report preparation and review procedures comply with relevant laws and regulations, and the report content truly, accurately and completely reflects the company's actual operating conditions in 2025, and does not contain any false records, misleading statements or major omissions.
The financial report part of this proposal has been reviewed and approved by all members of the Audit Committee of the company's board of directors.
For details, please refer to the "Summary of the 2025 Annual Report" (Announcement No.: 2026-011) and the "2025 Annual Report" (Announcement No.: 2026-012) disclosed by the company on the cninfo.com (www.cninfo.com.cn) on the same day. Voting results: 9 votes in favor, 0 votes against, and 0 abstentions. This motion was passed.
This proposal still needs to be submitted to the company's 2025 annual shareholders' meeting for review.
(2) Consideration and approval of the “Proposal on the Company’s 2025 Board of Directors Work Report”
In 2025, the company's board of directors strictly complied with the relevant provisions of laws, regulations, normative documents, and the "Articles of Association", "Rules of Procedure of the Board of Directors" and "Measures for the Management of Independent Directors of Listed Companies", conscientiously implemented various resolutions passed by the shareholders' meeting, conscientiously performed its duties, and continuously standardized the governance of the company.
The company's independent directors submitted the "2025 Independent Directors' Performance Report" to the board of directors and will take office at the company's 2025 annual shareholders' meeting.
The board of directors prepared the "Special Opinions of the Board of Directors on the Independence of Independent Directors" based on the "Self-examination Form on the Independence of Independent Directors" issued by the independent directors.
For details, please refer to the "2025 Board of Directors Work Report", "Special Opinions of the Board of Directors on Self-examination of the Independence of Independent Directors" and "2025 Independent Directors' Work Report" disclosed by the company on the cninfo.com (www.cninfo.com.cn) on the same day.
Voting results: 9 votes in favor, 0 votes against, and 0 abstentions. This motion was passed.
This proposal still needs to be submitted to the company's 2025 annual shareholders' meeting for review.
(3) Consideration and approval of the “Proposal on the Company’s 2025 General Manager Work Report”
The company's board of directors carefully listened to the "2025 General Manager Work Report" made by general manager Xie Zubin, and believed that the company's operating management effectively implemented various resolutions of the board of directors and shareholders' meeting in 2025, enabling the company to maintain sustained and stable development. The report objectively and truly reflects the main work of the operating management in 2025. Voting results: 9 votes in favor, 0 votes against, and 0 abstentions. This motion was passed.
(4) Consideration and approval of the “Proposal on the Company’s 2025 Internal Control Evaluation Report”
After deliberation, the board of directors believes that the company has established a relatively complete internal control system and can effectively implement it. The "2025 Internal Control Evaluation Report" objectively and truly reflects the construction and operation of the company's internal control system.
The audit committee of the company's board of directors has reviewed and approved the proposal, and the audit agency has issued an internal control audit report. For details, please refer to the "2025 Internal Control Evaluation Report" disclosed by the company on the cninfo website (www.cninfo.com.cn) on the same day.
Voting results: 9 votes in favor, 0 votes against, and 0 abstentions. This motion was passed.
(5) Consideration and approval of the “Proposal on the Company’s 2025 Financial Final Accounts Report”
After review, the board of directors believes that the company's "2025 Financial Final Report" objectively and truly reflects the company's financial status, operating results and cash flow in 2025.
The audit committee of the company's board of directors has reviewed and approved the proposal.
Voting results: 9 votes in favor, 0 votes against, and 0 abstentions. This motion was passed.
This proposal still needs to be submitted to the company's 2025 annual shareholders' meeting for review.
(6) Consideration and approval of the “Proposal on the Company’s Profit Distribution Plan for 2025”
In accordance with the guidance of the China Securities Regulatory Commission on encouraging listed companies to distribute cash dividends and provide investors with stable and reasonable returns, combined with the provisions of the "Company Law" and the "Articles of Association", taking into account the company's current development stage and the interests and reasonable demands of the majority of investors, especially small and medium-sized investors, the 2025 profit distribution plan is now formulated:
Based on the company's existing total share capital of 115,281,113 shares, excluding 1,069,600 shares that have been repurchased, which is 114,211,513 shares, a cash dividend of 0.45 will be distributed to all shareholders for every 10 shares. Yuan (tax included), a total cash dividend of 5,139,518.09 yuan (tax included) was distributed, no bonus shares were given, no capital reserve was converted into share capital, and the remaining accumulated undistributed profits were carried forward and distributed in subsequent years.
The audit committee of the company's board of directors and the special meeting of independent directors have reviewed and approved the proposal.
For details, please refer to the "Announcement on the Company's 2025 Profit Distribution Plan" (announcement number: 2026-013) disclosed by the company on the cninfo.com (www.cninfo.com.cn) on the same day.
Voting results: 9 votes in favor, 0 votes against, and 0 abstentions. This motion was passed.
This proposal still needs to be submitted to the company's 2025 annual shareholders' meeting for review.
(7) Deliberation and approval of the "Proposal on the Company's Provision for Asset Impairment and Credit Impairment in 2025" After deliberation, the board of directors believes that: the company's current provision of impairment losses complies with the relevant provisions of the "Accounting Standards for Business Enterprises" and can fairly reflect the company's financial status and operating results, and agrees with the company's current provision of impairment losses. The audit committee of the company's board of directors has reviewed and approved the proposal.
For details, please refer to the "Announcement on the Company's Provision for Asset Impairment and Credit Impairment in 2025" disclosed on the cninfo.com (www.cninfo.com.cn) on the same day (announcement number: 2026-014).
Voting results: 9 votes in favor, 0 votes against, and 0 abstentions. This motion was passed.
(8) Consider and approve the "Proposal on the Company and its Subsidiaries' Application for Comprehensive Credit Lines and Provision of Guarantees from Financial Institutions in 2026"
After deliberation, the board of directors believes that the application for a comprehensive credit line and provision of guarantees from financial institutions is to meet the capital needs for the business development of the company and its subsidiaries, to promote the company's 2026 development plan in an orderly manner, and is in line with the overall interests of the company. The guaranteed object is a subsidiary of the company. Its operating situation is stable, its financial risks are within an effective controllable range, and it has good solvency. The risk of providing a guarantee for it is controllable.
The company proposes to the shareholders' meeting to authorize the person in charge of the company's finance department to handle specific matters such as applying for credit and borrowing. The authorization period starts from the date of review and approval at the company's 2025 annual shareholders' meeting and ends on the date the resolution is made at the 2026 annual shareholders' meeting.
For details, please refer to the "Announcement on the Company and its Subsidiaries' Application for Comprehensive Credit Lines and Guarantees from Financial Institutions in 2026" disclosed by the company on the cninfo.com (www.cninfo.com.cn) on the same day (announcement number: 2026-015).
Voting results: 9 votes in favor, 0 votes against, and 0 abstentions. This motion was passed.
This proposal still needs to be submitted to the company's 2025 annual shareholders' meeting for review, and must be passed by more than 2/3 of the voting rights held by shareholders and shareholders' proxies present at the meeting.
(9) Consideration and approval of the “Proposal on Proposed Re-appointment of the Accounting Firm”
The board of directors agreed to renew the appointment of Dasin Accounting Firm (Special General Partnership) as the company's audit agency for 2026. The appointment period will be within one year from the date of approval by the company's shareholders' meeting, and authorized the company's management to negotiate with Dasin Accounting Firm to determine its annual audit fees based on specific audit requirements and audit scope.
The audit committee of the company's board of directors has reviewed and approved the proposal.
For details, please refer to the "Announcement on the Proposed Re-appointment of the Accounting Firm" (Announcement No.: 2026-016) disclosed by the company on the cninfo.com (www.cninfo.com.cn) on the same day.
Voting results: 9 votes in favor, 0 votes against, and 0 abstentions. This motion was passed.
This proposal still needs to be submitted to the company's 2025 annual shareholders' meeting for review.
(10) Consideration and approval of the “Proposal on Voiding Part of the Restricted Stocks that have been granted but have not yet vested under the 2023 Restricted Stock Incentive Plan”
After deliberation, the board of directors believes that: in accordance with the relevant provisions of the "Measures for the Administration of Equity Incentives for Listed Companies" and the "Hubei Gongyong Pharmaceutical Co., Ltd. 2023 Restricted Stock Incentive Plan (Draft)", in view that 6 of the incentive objects who were granted restricted stocks are no longer eligible for incentive objects due to resignation, the board of directors agrees that the company will invalidate the 42,100 restricted stocks that have been granted but have not yet vested; the company's 2023 restricted stock incentive plan 2025 The annual performance did not meet the target, and the board of directors agreed to invalidate 158,600 restricted shares that had been granted to 24 in-service first-time incentive grant recipients but could not be vested in the third vesting period, and 67,750 restricted shares that had been granted to 8 in-service reserved grant incentive recipients but could not be vested in the second vesting period. A total of 268,450 restricted shares were voided this time.
The Remuneration and Appraisal Committee of the company's board of directors has reviewed and approved the proposal.
For details, please refer to the "Announcement on the Voiding of Part of the Restricted Stocks Granted but Not yet vested in the 2023 Restricted Stock Incentive Plan" disclosed by the company on the cninfo.com (www.cninfo.com.cn) on the same day (Announcement No.: 2026-017).
Related director Jiang Yiwen abstained from voting.
Voting results: 8 votes in favor, 0 votes against, 0 abstentions, and 1 vote to avoid. This motion was passed.
(11) Review of the “Proposal on the Remuneration Plan for Directors and Senior Management of the Company”
In order to further improve the company's incentive and restraint mechanism and effectively mobilize the work enthusiasm and creativity of the company's directors and senior managers, this plan has been specially formulated based on the proposal of the Remuneration and Assessment Committee of the Board of Directors and combined with the company's 2025 salary levels of directors and senior managers.
This proposal has been reviewed by the Remuneration and Appraisal Committee of the Company's Board of Directors. Since it involves the remuneration of all directors, based on the principle of prudence, all members abstained from voting on the proposal.
For details, please refer to the "Announcement on the Remuneration Plan for Directors and Senior Management" (Announcement No.: 2026-018) disclosed by the company on the cninfo.com (www.cninfo.com.cn) on the same day.
Voting results: 0 votes in favor, 0 votes against, 0 abstentions, and 9 avoidance votes.
Since all directors abstained from voting, this proposal still needs to be submitted to the company's 2025 annual shareholders' meeting for review.
(12) Review of the "Proposal on Amending the Company's "Remuneration Management System for Directors and Senior Management Personnel"" In accordance with the latest provisions of the Company Law, "Guidelines on the Articles of Association of Listed Companies", "Shenzhen Stock Exchange GEM Stock Listing Rules" and other relevant documents, and in light of the actual situation of corporate governance, the company has made corresponding revisions to the "Remuneration Management System for Directors and Senior Management Personnel".
This proposal has been reviewed by the Remuneration and Appraisal Committee of the Company's Board of Directors. Based on the principle of prudence, all members abstained from voting on the proposal.
For details, please refer to the "Remuneration Management System for Directors and Senior Management Personnel" disclosed by the company on the cninfo.com (www.cninfo.com.cn) on the same day.
Voting results: 0 votes in favor, 0 votes against, 0 abstentions, and 9 avoidance votes.
Since all directors abstained from voting, this proposal still needs to be submitted to the company's 2025 annual shareholders' meeting for review.
(13) Consideration and adoption of the "Proposal on the Establishment of the "Information Disclosure Suspension and Exemption Management System""
In order to regulate the suspension and exemption of information disclosure by the company and other information disclosure obligors and strengthen the management of information disclosure, the company has formulated the "Information Disclosure Suspension and Exemption Management System" in accordance with the "Regulations on the Management of Information Disclosure Suspension and Exemption of Listed Companies", "Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 2 - Standardized Operation of GEM Listed Companies" and other laws, administrative regulations, normative documents and the "Articles of Association", and based on the actual situation, the company has formulated the "Information Disclosure Suspension and Exemption Management System".
For details, please refer to the "Information Disclosure Suspension and Exemption Management System" disclosed by the company on the cninfo website (www.cninfo.com.cn) on the same day.
Voting results: 9 votes in favor, 0 votes against, and 0 abstentions. This motion was passed.
(14) Consideration and approval of the "Proposal on the Proposal to Change the Company's Name and Amend the Articles of Association"
In order to better implement the company's group development strategy and improve the efficiency of group operation and management, the company plans to change its name from "Hubei Tongyong Pharmaceutical Co., Ltd." to "Hubei Tongyong Pharmaceutical Group Co., Ltd.". In order to facilitate the coordinated development of the business segments of each subsidiary, the "Articles of Association" will be updated simultaneously, and the company's securities code and securities abbreviation will remain unchanged.
The company requests the shareholders' meeting to authorize the person designated by the company's board of directors to handle the industrial and commercial change registration, articles of association filing and other matters related to the name change. The authorization is valid from the date of review and approval by the shareholders' meeting to the date when the relevant industrial and commercial change registration and articles of association filing are completed. The final changes are subject to approval and registration by the market supervision and management department.
For details, please refer to the "Announcement on the Proposed Change of the Company's Name and the Revision of the Articles of Association" disclosed by the company on the cninfo.com (www.cninfo.com.cn) on the same day (announcement number: 2026-019).
Voting results: 9 votes in favor, 0 votes against, and 0 abstentions. This motion was passed.
This proposal still needs to be submitted to the company's 2025 annual shareholders' meeting for review, and must be passed by more than 2/3 of the voting rights held by shareholders and shareholders' proxies present at the meeting.
(15) Consider and approve the “Proposal on the 2026 Restricted Stock Incentive Plan (Draft) of Hubei Kyodo Pharmaceutical Co., Ltd.” and its summary
In order to further establish and improve the company's long-term incentive and restraint mechanism, attract and retain outstanding talents, fully mobilize the enthusiasm of the company's core team, effectively combine the interests of shareholders, the company's interests and the core team's personal interests, so that all parties can jointly pay attention to the company's long-term development, in accordance with the "Company Law of the People's Republic of China", "Equity Incentive Management Measures for Listed Companies" and "Shenzhen Stock Exchange GEM Listed Companies Self-Discipline Supervision Guidelines No. 1" No. - Business Processing" and other relevant laws and regulations, the company has drafted the "Hubei Tongyong Pharmaceutical Co., Ltd. 2026 Restricted Stock Incentive Plan (Draft)" and its summary.
The Remuneration and Appraisal Committee of the company's board of directors has reviewed and approved the proposal.
For details, please refer to the "Hubei Tongyong Pharmaceutical Co., Ltd. 2026 Restricted Stock Incentive Plan (Draft)" and its summary disclosed by the company on the cninfo.com (www.cninfo.com.cn) on the same day.
Related directors Zu Bin, Xi Siyi, Wang Xueming, Jiang Yiwen and Liu Xiangdong have abstained from voting.
The voting results were: 4 votes in favor, 0 votes against, 0 abstentions, and 5 votes to avoid.
This proposal still needs to be submitted to the company's 2025 annual shareholders' meeting for review, and must be passed by more than 2/3 of the voting rights held by shareholders and shareholders' proxies present at the meeting.
(16) Consideration and approval of the "Proposal on the Implementation Assessment and Management Measures for the 2026 Restricted Stock Incentive Plan of Hubei Kyodo Pharmaceutical Co., Ltd."
In order to ensure the smooth progress of the company's 2026 Restricted Stock Incentive Plan (hereinafter referred to as the "Incentive Plan") and the realization of the company's development strategy and business goals, in accordance with the "Company Law of the People's Republic of China", "Equity Incentive Management Measures for Listed Companies" and "Shenzhen Stock Exchange's GEM Self-Regulatory Guidelines for Listed Companies No. 1" No. - Business Processing" and other relevant laws, regulations and normative documents, as well as the provisions of the "Articles of Association" and "Hubei Gongyong Pharmaceutical Co., Ltd. 2026 Restricted Stock Incentive Plan (Draft)", combined with the actual situation of the company, the "Hubei Gongyang Pharmaceutical Co., Ltd. 2026 Restricted Stock Incentive Plan Implementation Assessment and Management Measures" were formulated. The Remuneration and Appraisal Committee of the company's board of directors has reviewed and approved the proposal.
For details, please refer to the "Measures for the Implementation Assessment and Management of the 2026 Restricted Stock Incentive Plan of Hubei Tongyong Pharmaceutical Co., Ltd." disclosed by the company on the cninfo.com (www.cninfo.com.cn) on the same day.
Related directors Zu Bin, Xi Siyi, Wang Xueming, Jiang Yiwen and Liu Xiangdong have abstained from voting.
The voting results were: 4 votes in favor, 0 votes against, 0 abstentions, and 5 votes to avoid.
This proposal still needs to be submitted to the company's 2025 annual shareholders' meeting for review, and must be passed by more than 2/3 of the voting rights held by shareholders and shareholders' proxies present at the meeting.
(17) Consider and approve the "Proposal on Requesting the Shareholders' Meeting to Authorize the Board of Directors to Handle Matters Related to the Company's 2026 Restricted Stock Incentive Plan"
In order to ensure the smooth implementation of the company's incentive plan, the company's board of directors requested the shareholders' meeting to authorize the board of directors to handle the following matters related to the company's incentive plan:
- Request the company’s shareholders’ meeting to authorize the board of directors to be responsible for the specific implementation of the following matters of this incentive plan:
(1) Authorize the board of directors to determine the qualifications and conditions for the incentive targets to participate in this incentive plan, determine the list of incentive targets and their number of grants, determine the grant price of restricted stocks and the grant date of the company's incentive plan; (2) Authorize the board of directors to make corresponding adjustments to the number of restricted stock grants/vesting in accordance with the methods stipulated in this incentive plan when the company has issues such as converting capital reserves to increase share capital, distributing stock dividends, stock splits or reductions, allotments, etc.;
(3) Authorize the board of directors to make corresponding adjustments to the restricted stock grant price in accordance with the methods stipulated in this incentive plan when the company has issues such as converting capital reserves into equity, distributing stock dividends, stock splits or reductions, allotments, dividends, etc.;
(4) Authorize the board of directors, before the grant of restricted stocks, to adjust the share of authorized benefits voluntarily given up by the incentive recipients due to resignation or personal reasons to the reserved portion or to distribute or directly reduce the shares among the incentive recipients;
(5) Authorize the board of directors to grant restricted stocks to the incentive targets when the incentive targets meet the conditions and handle all matters necessary for the grant of restricted stocks, including but not limited to signing the "Restricted Stock Grant Agreement" with the incentive targets;
(6) Authorize the board of directors to review and confirm the vesting qualifications, vesting conditions, and vesting amounts of the incentive objects, and agree with the board of directors to grant this right to the remuneration and assessment committee of the board of directors for exercise;
(7) Authorize the board of directors to handle all matters necessary for the vesting of the incentive object's restricted stocks, including but not limited to filing vesting applications with the Shenzhen Stock Exchange, applying to the China Securities Depository and Clearing Co., Ltd. Shenzhen Branch for relevant registration and settlement business, amending the Articles of Association, and registering changes to the company's registered capital, etc.;
(8) Authorize the board of directors to decide whether the restricted stocks granted to the incentive targets can be vested;
(9) Authorize the board of directors to determine all matters including the incentive objects, grant quantity, grant price and grant date of the company’s reserved restricted stocks in this incentive plan;
(10) Authorize the board of directors to handle matters related to the change and termination of this incentive plan in accordance with the provisions of this incentive plan, including but not limited to canceling the vesting qualifications of the incentive objects, canceling the invalidation of the unvested restricted stocks of the incentive objects, handling the inheritance of the unvested restricted stocks of the deceased incentive objects, etc.; according to the provisions of this incentive plan, decide whether to recover the income obtained from the vesting of the incentive objects;
(11) Authorize the board of directors to sign, execute, modify, and terminate any agreements and other related agreements related to this incentive plan;
(12) Authorize the board of directors to manage and adjust the company's incentive plan, and formulate or modify the management and implementation regulations of the plan from time to time on the premise that it is consistent with the terms of this incentive plan. However, if laws, regulations or relevant regulatory agencies require such modifications to be approved by the shareholders' meeting or/and relevant regulatory agencies, such modifications by the board of directors must be approved accordingly;
(13) Authorize the board of directors to carry out other necessary matters required for the implementation of this incentive plan, except for the rights clearly stipulated in the relevant documents that need to be exercised by the shareholders' meeting.
Request the company's shareholders' meeting to authorize the board of directors to go through the approval, registration, filing, approval, and consent procedures with relevant governments and institutions for this incentive plan; sign, execute, modify, and complete documents submitted to relevant governments, institutions, organizations, and individuals; amend the Articles of Association, register changes in the company's registered capital (including capital increase, capital reduction, etc.); and perform all actions that it deems necessary, appropriate, or appropriate in connection with this incentive plan.
Request the company's shareholders' meeting to authorize the board of directors to appoint financial consultants, collecting banks, accounting firms, law firms, securities companies and other intermediaries for the implementation of this incentive plan.
Request approval from the company’s shareholders’ meeting that the authorization period for the board of directors be consistent with the validity period of this incentive plan. Except for matters clearly stipulated in relevant laws, administrative regulations, China Securities Regulatory Commission rules, normative documents, Articles of Association and other documents that need to be approved by the board of directors, other matters may be directly exercised by the chairman of the board of directors or the appropriate person authorized by him on behalf of the board of directors.
Related directors Zu Bin, Xi Siyi, Wang Xueming, Jiang Yiwen and Liu Xiangdong have abstained from voting.
The voting results were: 4 votes in favor, 0 votes against, 0 abstentions, and 5 votes to avoid.
This proposal still needs to be submitted to the company's 2025 annual shareholders' meeting for review, and must be passed by more than 2/3 of the voting rights held by shareholders and shareholders' proxies present at the meeting.
(18) Consideration and approval of the “Proposal on the Company’s First Quarterly Report of 2026”
After deliberation, the board of directors believes that the preparation and review of the company's "2026 First Quarter Report" complies with relevant laws and regulations. The content of the report is true, accurate and complete, and does not contain any false records, misleading statements or major omissions.
The financial report part of this proposal has been reviewed and approved by all members of the Audit Committee of the company's board of directors.
For details, please refer to the "2026 First Quarter Report" (announcement number: 2026-020) disclosed by the company on the cninfo.com (www.cninfo.com.cn) on the same day.
Voting results: 9 votes in favor, 0 votes against, and 0 abstentions. This motion was passed.
(19) Consideration and approval of the "Proposal on Requesting the Shareholders' Meeting to Authorize the Board of Directors to Handle the Issuance of Stocks to Specific Objects through Simple Procedures"
The board of directors agreed to request the shareholders' meeting to authorize the board of directors to issue stocks with a total financing amount of no more than RMB 300 million and no more than 20% of the net assets at the end of the most recent year to specific objects through a simplified procedure. The authorization period is from the date of approval by the 2025 annual shareholders' meeting to the date of the 2026 annual shareholders' meeting.
For details, please refer to the "Announcement on Requesting the Shareholders' Meeting to Authorize the Board of Directors to Handle the Issuance of Stocks to Specific Objects through Simple Procedures" disclosed by the company on the cninfo.com (www.cninfo.com.cn) on the same day (announcement number: 2026-021).
Voting results: 9 votes in favor, 0 votes against, and 0 abstentions. This motion was passed.
This proposal still needs to be submitted to the company's 2025 annual shareholders' meeting for review, and must be passed by more than 2/3 of the voting rights held by shareholders and shareholders' proxies present at the meeting.
(20) Consideration and approval of the “Proposal on Proposing to Convene the Company’s 2025 Annual Shareholders’ Meeting”
In accordance with relevant regulations such as the "Articles of Association" and "Shenzhen Stock Exchange GEM Stock Listing Rules", after review by the directors present at the meeting, it was agreed that the company would hold the 2025 Annual Shareholders Meeting at the company site at 14:00 on May 19, 2026 (Tuesday) through a combination of on-site voting and online voting.
For details, please refer to the "Notice on Convening the 2025 Annual Shareholders Meeting" (announcement number: 2026-022) disclosed by the company on the cninfo.com (www.cninfo.com.cn) on the same day.
Voting results: 9 votes in favor, 0 votes against, and 0 abstentions. This motion was passed.
3. Documents for reference
Resolution of the 13th meeting of the third board of directors;
Resolution of the second meeting of the Audit Committee of the Board of Directors in 2026;
Resolution of the second special meeting of independent directors in 2026;
Resolution of the first meeting of the Board of Directors’ Remuneration and Assessment Committee in 2026.
Announcement is hereby made.
Hubei Tongyong Pharmaceutical Co., Ltd. Board of Directors
April 28, 2026